Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Services
2023 Readersâ Choice Winners
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Catalyst Pharm Inc
(NQ:
CPRX
)
16.27
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
213
Open
16.27
Bid (Size)
16.30 (1)
Ask (Size)
16.56 (1)
Prev. Close
16.27
Today's Range
16.27 - 16.27
52wk Range
11.55 - 18.22
Shares Outstanding
102,780,151
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals
March 27, 2024
Via
Benzinga
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
March 27, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Performance
YTD
-4.91%
-4.91%
1 Month
+14.74%
+14.74%
3 Month
-5.90%
-5.90%
6 Month
+33.69%
+33.69%
1 Year
-0.61%
-0.61%
More News
Read More
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
March 27, 2024
Via
InvestorPlace
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
March 18, 2024
Via
InvestorPlace
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
March 18, 2024
Via
Investor's Business Daily
Assessing Catalyst Pharmaceuticals: Insights From 4 Financial Analysts
March 07, 2024
Via
Benzinga
Earnings Preview For Catalyst Pharmaceuticals
February 27, 2024
Via
Benzinga
Why Catalyst Pharmaceuticals Stock Is Trading Lower
January 05, 2024
Via
Benzinga
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
March 13, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
3 Sexy Small-Cap Stocks to Add Sizzle to Your Portfolio
March 10, 2024
Via
InvestorPlace
Amicus Therapeutics Stock Sees RS Rating Improve To 74
March 05, 2024
Via
Investor's Business Daily
3 Biopharma Stocks You Don't Want to Miss in the New Bull Market
March 05, 2024
Via
The Motley Fool
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
March 05, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Top 3 Health Care Stocks You May Want To Dump In Q1
February 29, 2024
Via
Benzinga
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 28, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
February 27, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology
February 21, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
February 14, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Jim Cramer Likes This Bank 'Very, Very Much,' Says Stock Is Up 7% Over Past 6 Months
January 22, 2024
Via
Benzinga
Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances
January 18, 2024
Via
InvestorPlace
Topics
Economy
Exposures
Economy
3 Biotech Stocks You Can Buy and Hold for the Next Decade
January 15, 2024
Via
The Motley Fool
Forget Shiba Inu: This Stock is Poised for a Potential Bull Run in 2024
January 14, 2024
Via
The Motley Fool
Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering
January 09, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
3 Unstoppable S&P 600 Small-Cap Stocks to Buy in January
January 08, 2024
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 05, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.